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Background: Despite two decades of interventions, rates of sexually transmissible infections (STI) in remote
Australian Aboriginal communities remain unacceptably high. Routine notifications data from 2011 indicate rates of
chlamydia and gonorrhoea among Aboriginal people in remote settings were 8 and 61 times higher respectively
than in the non-Indigenous population.
Methods/design: STRIVE is a stepped-wedge cluster randomised trial designed to compare a sexual health
quality improvement program (SHQIP) to usual STI clinical care delivered in remote primary health care
services. The SHQIP is a multifaceted intervention comprising annual assessments of sexual health service
delivery, implementation of a sexual health action plan, six-monthly clinical service activity data reports,
regular feedback meetings with a regional coordinator, training and financial incentive payments. The trial
clusters comprise either a single community or several communities grouped together based on geographic
proximity and cultural ties. The primary outcomes are: prevalence of chlamydia, gonorrhoea and trichomonas
in Aboriginal residents aged 16–34 years, and performance in clinical management of STIs based on best
practice indicators. STRIVE will be conducted over five years comprising one and a half years of trial
initiation and community consultation, three years of trial conditions, and a half year of data analysis. The
trial was initiated in 68 remote Aboriginal health services in the Northern Territory, Queensland and
Western Australia.
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Discussion: STRIVE is the first cluster randomised trial in STI care in remote Aboriginal health services. The
trial will provide evidence to inform future culturally appropriate STI clinical care and control strategies in
communities with high STI rates.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12610000358044
Keywords: Aboriginal, Indigenous, Sexually transmitted infections, Chlamydia, Gonorrhoea, Trichomonas,
Continuous quality improvement, Protocol, Prevalence, RemoteBackground
For almost two decades sexually transmissible infection
(STI) diagnoses have occurred at hyperendemic rates in
many remote Australian Aboriginal and Torres Strait Is-
lander (hereafter referred to as ‘Aboriginal’) communities
[1]. Data on prevalent and incident infection in these
settings are derived from routine notifications reportable
by public health agencies and sporadic prevalence sur-
veys conducted in the context of screening programs [2].
In 2011 the diagnosis rates of Chlamydia trachomatis
(chlamydia) and Neisseria gonorrhoeae (gonorrhoea)
among Aboriginal people resident in remote communi-
ties were 8 and 61 times greater than in the non-
Indigenous population [1]. A similar situation exists for
Trichomonas vaginalis (trichomonas) in the Northern
Territory, the only jurisdiction which requires notifica-
tion of this infection [3]. The majority of these three
STIs are notified among people aged 15–29 years [1].
While differential patterns of testing may play some
role in these discrepant rates of diagnosis, a major
component of the disparity [1] is almost certainly attribut-
able to inadequate access to early detection and appropri-
ate treatment programs offered in primary health care
settings [4].
Chlamydia, gonorrhoea, and trichomonas are fully cur-
able STIs but are often asymptomatic for long periods and
can lead to serious complications if untreated [5]. For ex-
ample, untreated chlamydia infection may potentially cause
pelvic inflammatory disease (PID), ectopic pregnancy and
tubal factor infertility among women [6,7]. In the Top End
of the Northern Territory, 26% of all Aboriginal women
were found to have had history of PID [8]. Chlamydia can
also result in adverse pregnancy outcomes including pre-
mature labour and birth, low birth weight, intrauterine
growth restrictions, postpartum endometritis [9,10] and a
range of neonatal infections including infectious conjunc-
tivitis and pneumonitis [5]. Gonorrhoea has similar seque-
lae to chlamydia and can also lead to disseminated
infection [5]. Trichomoniasis among women is associated
with premature rupture of membranes, premature delivery
and low birth weight [11,12] while trichomoniasis in men
is an important cause of non gonococcal urethritis and is
associated with prostatitis [13,14]. All three STIs are asso-
ciated with an increased risk of HIV transmission [15,16].STI programs in remote aboriginal communities
Despite many years of effort aimed at reducing the inci-
dence and prevalence of STIs in remote communities, it
is speculated that increased support to primary care is
required to achieve best practice in the clinical manage-
ment of STIs. In this setting, staff turnover is high and
the burden of chronic disease, other infectious diseases,
and child and maternal health needs is particularly high
[17,18]. Given that resources are finite, particularly in re-
gard to the availability of clinical personnel, several ap-
proaches have been used to support specialised areas of
health service need in remote communities. One method
has been to appoint specialist visiting personnel to pro-
vide service delivery in primary care settings at a re-
gional level, focusing exclusively on the area of need
[2,19,20]. These activities are recognized as having the
fundamental limitation that they are unlikely to be well
enough resourced to provide specialised assistance to all,
or even a high percentage, of clinical episodes. In the
area of sexual health, population screening has been
used in some communities to improve testing coverage,
but generally these programs depend on outside teams
providing a service within a limited time frame, and may
not always contribute to the confidence and competence
of local clinical staff.
In addition to detecting and treating infections, a
major goal of improving sexual health service delivery is
to reduce the overall prevalence of infections. Analyses
of program data to compare changes in STI prevalence
over time in communities with different levels of service
activity provide some insight into the effectiveness of
programs [2], but their interpretation is compromised by
a number of potential confounding effects. These effects
include differences between communities, such as size
and mobility of the population, sexual networks and the
extent of treatment-seeking behaviours [2], all of which
are difficult to monitor systematically. Another approach
is to randomly allocate selected communities to receive
a program of support over a defined time period to en-
hance STI diagnosis and treatment to best practice levels
and to compare outcomes with control communities.
This approach has been trialed in remote primary health
care services addressing improvements in quality of care
related to chronic disease [17,21-23].
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1. To determine whether targeted support to health
services can achieve substantive and sustained
improvements in the provision of sexual health clinical
services in remote Aboriginal communities; and
2. To determine whether the attainment of best
practice levels in clinical activity can reduce the
prevalence of curable STIs in these communities.
Methods
Study design
STRIVE is a community-based stepped-wedge cluster
randomised controlled trial. During the first 18 months
of the trial, 24 ‘trial clusters’ comprising 68 remote com-
munities and primary care centres in Central and North-
ern Australia were recruited to participate in the trial,
and undergo preparatory procedures. The trial clusters
are the unit of randomization and comprise either a sin-
gle community or several communities that share close
cultural affinities and/or are geographically proximal.
The clusters were determined by the research team in
consultation with stakeholders and are located in remote
Australia, in the Northern Territory (18 clusters), West-
ern Australia (3 clusters) and Queensland (3 clusters).
At the start of each of the three years, one third of the
clusters are randomly assigned to receive the SHQIP (see
Figure 1). Clusters not randomised to receive the SHQIP
continue to undertake usual STI care. By the start of year
four, all clusters will be receiving the SHQIP.
The stepped-wedge design [24] ensures that all com-
munities and their health services in the trial receive the
SHQIP. Given that this design enables the intervention
to be delivered to all clusters and that the intervention is
likely to have a potential beneficial effect [25] it was af-
firmed as a preferred model with key stakeholders.
Chlamydia, gonorrhoea and trichomonas are good candi-
dates for clinical quality improvement strategies because they
are endemic in remote Aboriginal communities and can be
easily diagnosed and treated. Moreover in the same commu-
nities infectious syphilis [26] and donovanosis [27] have
declined significantly over the last decade as a result of
sustained and specific targeted clinical programs. While
STRIVE focuses on the three specified STIs, it also encour-
ages ‘best practice’ for the detection and treatment of all STIs.
Ethics and informed consent
During 2009–2010 the STRIVE study protocol was approved
by the Central Australian Human Research Ethics Commit-
tee, the Cairns and Hinterland Human Research Ethics
Committee, the Human Research Ethics Committee of the
Northern Territory Department of Health and Menzies
School of Health Research, the University of New South
Wales Human Research Ethics Committee, the WesternAustralian Aboriginal Health Information Ethics Commit-
tee, and the Western Australian Country Health Service
Board Research Ethics Committee.
Participating health services signed a site participation
agreement prior to commencement of their involvement
in STRIVE. Consultation and laboratory data are col-
lected through routine patient management systems.
Community engagement and collaborations
A key underlying principle of STRIVE is effective engage-
ment at all stages with stakeholders including government,
non-government organisations and the community. Ex-
tensive community engagement occurs through multiple
modes including engagement with key stakeholders, an
initial community engagement workshop and constant
communication with participating health services.
Identification of communities and health services and
eligibility criteria
For inclusion in STRIVE, communities must be considered
remote by the Australian Bureau of Statistics [28]; have a
resident population of at least 100 Aboriginal people aged
16–34 years and Aboriginal people must comprise a major-
ity of the population; have a health service willing to par-
ticipate based on the trial protocol including an ability to
provide access to de-identified clinical data throughout the
trial. Study personnel determined eligibility of communities
and health services to participate. All eligible communities
and health services within each trial cluster were invited to
participate. Conversely a community is not eligible if there
are multiple health services in that community.
Randomisation
Towards the end of the preparatory period, eight trial
clusters (designated “first year trial clusters”) were ran-
domly selected to receive the SHQIP in the second year.
Towards the end of the second year of STRIVE, a fur-
ther eight trial clusters were randomly allocated to the
SHQIP in the third year and fourth years.
Randomisation occurs after participation agreements
have been signed and the baseline STI prevalence survey
has been conducted. Trial clusters are randomised to the
SHQIP or usual care using a minimisation approach that
aims to balance population testing coverage rates, cluster
population size and geographic region across the baseline
levels in each trial cluster. The statistician, who was
blinded to the study sites (regions), prepared the random-
isation list for each geographical area. The protocol was
implemented in four regions of Australia in mid 2010.
Baseline activities conducted with participating health services
At enrolment, all participating primary care services under-
take three preparatory steps, supported by one of the
STRIVE study coordinators, each of whom works on a
All health services in clusters invited to participate
Health services sign participation agreement
Site description assessment 
Patient information management system upgrade
Randomise
24 ‘trial clusters’ identified
Trial clusters under TRIAL conditions
Sexual Health Quality Improvement 
Program
Year 2: 14
Year 3: 21
Control trial clusters under usual STI care 
Year 1: 16
Year 2: 8
8 trial clusters 
each year
Baseline
Undertake Systems 
Assessment
Develop Action Plan
Facilitate training required
En
ga
ge
m
en
t a
n
d 
Pr
e
pa
ra
tio
n
R
an
do
m
ise
d 
Co
n
tro
lle
d 
Tr
ia
l 
Annually
Update Site and Systems  
Assessment
STI prevalence study
Six-monthly
Feedback meetings
Review Action Plan 
STI prevalence study
Annually
STI prevalence study
Analysis and final reporting
Analysis
Report, incentives
Consultation
Health 
services, 
communities, 
Clinical data
Figure 1 STRIVE study process.
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tion on the health service context (staffing, location, path-
ology provider, patient information management system)and both current and past sexual health activities;
Step 2 involves the development and installation of an
upgraded STI template within the service’s patient
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by the coordinator of training and support to conduct a
STI prevalence survey with the service.
The sexual health quality improvement program (SHQIP)
The SHQIP is the intervention that takes place at each
health service, beginning in the year that the cluster to
which it belongs is selected by the randomisation
process. It is a multifaceted program, that involves an
annual assessment covering six key areas considered as
STI best practice (a systems assessment) followed by the
development of an action plan, both undertaken with
the support of a STRIVE coordinator. At six-monthly in-
tervals, the service (both management and clinical staff )
receives quantitative reports from patient information
systems and laboratory data on clinical activities based
on a set of quality indicators (see Table 1) and partici-
pates in collaborative feedback meetings with STRIVE
coordinators to review and address needs in sexual
health clinical service delivery. The coordinators also
identify and address requirements for training in sexual
health service delivery. Services assigned to the SHQIP
receive a one-off payment of $2,000 to support health
promotion activities aimed at increasing clinical visits
for STI testing by young people, and at six monthly in-
tervals they receive payments calculated on the basis of
their performance against the best practice indicators
(described below).
Systems assessment
STRIVE coordinators work collaboratively with health
service staff to assess the current status of sexual health
service delivery using a self-assessment tool based on
the methods of the Audit and Best Chronic Disease Ex-
tension program [29], The tool enables any gaps in STI
care and management to be identified, and exploresTable 1 STI best practice indicators
STI best practice indicators Target
Proportion of Aboriginal patients aged 16–34 years old
who have an annual test for chlamydia, gonorrhoea
and trichomonas
80%
Proportion of health service patients presenting with
STI symptoms who receive immediate treatment
95%
Proportion of people diagnosed by laboratory test with
chlamydia, gonorrhoea or trichomonas who are treated
within seven days of the test result being received from
the laboratory
80%
Proportion of patients found by laboratory test to have
chlamydia, gonorrhoea or trichomonas who have a test
for re-infection at between two to four months following
treatment
80%
Proportion of named sexual contacts, of people found to
have chlamydia, gonorrhoea or trichomonas, tested and
treated
50%ways to improve sexual health clinical services in rela-
tion to the diagnosis and management of STIs. The sys-
tems assessment covers six areas; including health
hardware, clinical services, information systems, health
promotion, organisational commitment, surveillance and
evaluation. Staff score their health service on an 11-
point scale in each area, with an aim of improving areas
at subsequent annual assessments. The areas cover the
fundamental components of a comprehensive sexual
health program identified for the remote primary health
care setting [30].
Best practice STI indicators
The indicators established for STRIVE (Table 1) are based
on current guidelines for best practice in STI care and
management [31-33]. According to these guidelines,
young people at risk of STIs should have a test for
chlamydia, gonorrhoea and trichomonas every year;
syndromically treated at consultation, and as soon as
possible following a laboratory diagnosis. Those treated
for an infection(s) should be asked to refer or name
sexual contacts to clinic staff, and return for a test for
re-infection for gonorrhoea and chlamydia at three
months. The indicators in Table 1 are discussed with
health service staff at the first systems assessment
meeting, and form the basis for subsequent reports on
performance. Each indicator is calculated for six month
periods, apart from the annual screen. Indicator calcula-
tions are based on Aboriginal residents as determined by
the health service.
Sexual health action plan
The action plan is based on the outcome of the annual
systems assessment and is developed by health services
supported by STRIVE coordinators to guide strategies
for the health services over the next year of the trial and
aimed at improving sexual health service delivery. The
strategies may involve better application of existing proce-
dures. For example discussion of STI best practice at
weekly service meetings and regular data review, or new
innovations such as STI testing visual reminder cards
placed in clinics; implementing systematic approaches for
collection of urine specimens and ensuring electronic re-
calls are installed within patient information management
systems. The action plan is reviewed at three months and
updated six monthly following the site visits.
Indicator reports
Health service staff and managers are provided with six
monthly reports based on the best practice indicators, to
discuss at the feedback meetings. These quantitative re-
ports show the extent of improvements towards the tar-
gets. In addition to the best practice indicators, the
reports also provide information on the proportion of
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attended the health service during the period. Population
denominators are derived from the number of Aborigi-
nal residents who attended the health service in the pre-
ceding two years.
Clinical performance payments
After randomisation to the SHQIP, health services re-
ceive incentive payments on a six monthly basis, except
for testing coverage, which is assessed annually. Pay-
ments are calculated on the basis of progress towards
best practice targets. Services receive payments of $100
(AUD) for each episode of treating patients with STI
symptoms at consultation; for treating a person diag-
nosed with an STI within seven days of the laboratory
result being received at the clinic; and for re-testing each
individual diagnosed with an STI at three months. Ser-
vices also receive $100 per contact tested and treated
within two weeks of being named. For a 10% or more
improvement in any indicator in the subsequent period,
the service receives a $500 payment. Services which
reach the targets receive an additional $500, once only.
Data collection methods and variables
The trial uses a number of methods to collect data
(Table 2).Table 2 Tools, methods and description of information collec
Tool Method and frequency
Site description assessment • Conducted by regional STRIVE Coordinator
and the start of each year in all health serv
• Updated annually with any contextual info
may impact on delivery of STI services
Systems Assessment • Conducted by regional STRIVE Coordinator
health services randomised to the SHQIP
Quantitative STI testing and
clinical management data
• Collated from one or more of the followin
(i) Health service patient information manag
(ii ) STI templates within patient manageme
(iii) Contact tracing forms
(iv) Laboratory data
• Extracted 6 monthly for all health services
STI prevalence assessment • Each person attending the clinic aged 16-3
offered a STI screening test for all three ST
• 50 men and 50 women from each cluster
included
• Takes place on an annual basis in all healthPrevalence assessment
At the start of each year and prior to initial randomisa-
tion the prevalence of chlamydia gonorrhoea and tricho-
monas will be assessed in clients attending participating
health services. The assessment will involve screening 50
male and 50 female resident clients aged 16–34 years
per cluster. All those in the age group attending the
health service in the prevalence assessment period will
be offered testing, unless they have had a test within the
preceding three months. For clusters with more than
one primary health care centre, the target numbers of 50
men and women will be allocated proportionately
according to the number of health services and the size
of the community served. The prevalence will be
assessed again at the end of the study (Figure 1).
Outcome measures
Primary outcomes are:
1. Prevalence of chlamydia, gonorrhoea or trichomonas
in male and female Aboriginal residents aged 16–
34 years, as measured using the trial prevalence
assessment (Table 2); and
2. Performance in clinical service activity based on the
best practice indicators over the period of the trial
(Table 1).ted in the trial
Description of data collected
s at baseline
ices
Broad description of:
rmation that (i) Current sexual health activities, including health
promotion activities
s annually in Information on:
(i) Health hardware
(ii) Clinical services
(iii) Patient information systems
(iv) Health promotion
(v) Organizational commitment to sexual health
(vi) Surveillance and evaluation
g sources: (i) Patient consultation data and associated
demographics
ement systems (ii) STI testing, retesting and treatment outcomes
Laboratory test result
nt systems
4 will be
Is
(i) Prevalence of chlamydia, gonorrhoea and
trichomonas in 16-34 year olds in STRIVE trial clusters
will be
services
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der, patient age group (16–19, 20–24, 25–29, 30–
34 years), STI type, and the reason for attendance.
Secondary outcomes are:
1. Diagnoses of pelvic inflammatory disease (PID) and
epididymitis
2. Feasibility and acceptability of research conducted in
remote primary care settings.
Sample size
Power calculations were performed using the method of
Hayes and Bennet [34] for cluster randomised trials. Es-
timates of between and within cluster variability in the
primary end point were based on prevalence of the se-
lected STIs in 2006 (the most recent prevalence data
available) among Aboriginal people aged 14–34 years in
central Australia [35]. Prevalence of chlamydia and gon-
orrhoea was estimated to be 15%, with an average 65
people tested in each cluster for chlamydia and gonor-
rhoea. Based on the 2006 notification data, between
community variability was estimated as corresponding
to a standard deviation of 8.45%, and the within commu-
nity co-efficient of variation of 0.42. A total of 14 clus-
ters are needed to detect a reduction in chlamydia and
gonorrhea prevalence from 15% in control clusters to
7.5% in SHQIP clusters with 80% power and allowing for
differing average numbers of people screened in each clus-
ter (2-alpha = 0.05, with no adjustments for multiple com-
parisons), and equal numbers of clusters in each arm.
Statistical analysis plan
Primary analysis will compare randomised clusters using
an intention to treat approach. Characteristics of clusters
will be summarized at baseline and across study arms
(SHQIP or usual practice).
Analyses of the primary endpoint will be based on general-
ized linear mixed models to account for within and between
cluster variability. The generalized estimating equation ap-
proach, with robust standard errors, will be adopted, using
STATA 12.0 (College Station, TX, USA) statistical analysis
software. Initial analyses will be simple, unadjusted compari-
sons of randomised clusters. If there appear to be any im-
portant imbalances between randomised groups in terms of
baseline covariates, adjusted analyses will also be performed.
All effects will be estimated with a 95% confidence intervals
and p-values from the corresponding hypothesis tests. Statis-
tical significance will be taken as two sided p-value less than
0.05, with no adjustment for multiple comparisons.
There will be two main analyses. First, after one year
of follow-up there will be a comparison between the first
and second round communities, assessing the effect of
the intervention after one year. Second, after two years
follow-up there will be a comparison between the firstround and third round clusters, assessing the effect of
the intervention after two years. The investigators
recognize that a range of sexual health program activities
will be taking place across communities throughout the
duration of STRIVE. Systematic monitoring of these ac-
tivities as described in Table 2 will allow us to compare
them, both qualitatively and quantitatively, between
SHQIP and usual practice communities.
There are a few envisaged limitations to the STRIVE
protocol. Firstly the STRIVE study will determine if
implementing a CQI approach is effective in reducing STI
rates, but will not address the issue of testing for STIs
among community members who do not attend a health
service. At this point we do not know what proportion of
the community do not attend a health service, especially in
the younger age groups within the 16–34 year age bracket.
Secondly the STRIVE study is powered to detect a
50% decline in STI prevalence but it is possible that re-
ductions may be less than this. However, a 50% reduc-
tion in prevalence would still leave rates at between 4
and 30 times higher, and the level of STI care provided
after the SHQIP program will still be comparable to
what is provided in health services accessible to Austra-
lians not living in remote communities.
Other key challenges to STRIVE are those characteris-
tic of remote environments and include the need to sus-
tain the motivation of clinic staff to participate in
STRIVE while addressing the multiple competing health
priorities, as well as high staff turnover.
Discussion
Rates of STIs in remote Aboriginal communities in
Australia are unacceptably high and STRIVE will support
health services to achieve ‘best practice’ STI care by evalu-
ating the efficacy of a SHQIP in decreasing STI preva-
lence. A strength of STRIVE is its ethical and robust
design and large sample size of 68 remote communities.
To our knowledge, STRIVE is the largest randomised con-
trolled trial ever conducted among Aboriginal and/or
Torres Strait Islander adults in Australia. The trial out-
comes will enhance understanding of STI control and pro-
vide evidence of the effectiveness of SHQIPs in endemic
communities as program data do not provide sufficient
evidence of the effectiveness of programs.
Results will provide valuable and much needed infor-
mation to guide STI clinical practice and programs in
remote Aboriginal settings and other vulnerable com-
munities with endemic rates of STIs.
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